PARP the perpetrator; Chemokines in the spotlight; New life for tobacco

Guilford Pharmaceuticals Inc. demonstrated proof-of-principle for its stroke program in a Nature Medicine paper showing that mice deficient in an enzyme called poly(ADP-ribose) polymerase (PARP) are resistant to neurotoxicity and have reduced infarct volume after a stroke.

The work was done by scientists at Johns Hopkins University, which has granted GLFD (Baltimore, Md.) exclusive license to the use of PARP inhibitors to prevent neurotoxicity...